Preresection serum C-reactive protein measurement and survival among patients with resectable non-small cell lung cancer

Journal of Thoracic and Cardiovascular Surgery

Volumn 142, Issue 5, 2011, Pages 1161-1167

  Alifano, Marco ^a,b   Falcoz, Pierre E ^c   Seegers, Valérie ^a   Roche, Nicolas ^a   Schussler, Olivier ^a   Younes, Mohamad ^b   Antonacci, Filippo ^c   Forgez, Patricia ^b   Dechartres, Agnes ^a   Massard, Gilbert ^c   Damotte, Diane ^a,d   Régnard, Jean Franois ^a  

^a HÔTEL DIEU   (France)

^b CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHRONIC BRONCHITIS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; HYPOALBUMINEMIA; LOBECTOMY; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PARIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PULMONARY SURGICAL PROCEDURES; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 80055015450     PISSN: 00225223     EISSN: 1097685X     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2011.07.021     Document Type: Article

References (21)

1. D.C. McMillan Systemic inflammation, nutritional status and survival in patients with cancer Curr Opin Clin Nutr Metab Care 12 2009 223 226
2. F. Balkwill, and A. Mantovani Cancer and inflammation: implications for pharmacology and therapeutics Clin Pharmacol Ther 87 2010 401 406
3. G. Lazennec, and A. Richmond Chemokines and chemokine receptors: new insights into cancer-related inflammation Trends Mol Med 16 2010 133 144
4. K.H. Allin, S.E. Bojesen, and B.G. Nordestgaard Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer J Clin Oncol 27 2009 2217 2224
5. A.J. Alberg, J.G. Ford, and J.M. Samet Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition) Chest 132 3 Suppl 2007 29S 55S (Pubitemid 47502798)
6. P.J. Barnes, and B.R. Celli Systemic manifestations and comorbidities of COPD Eur Respir J 33 2009 1165 1185
7. M.B. Pepys, and G.M. Hirschfield C-reactive protein: a critical update J Clin Invest 111 2003 1805 1812 Erratum in: J Clin Invest. 2003;112:299 (Pubitemid 38057722)
8. T. Matsuguchi, S. Okamura, C. Kawasaki, K. Shimoda, F. Omori, and S. Hayashi Constitutive production of granulocyte colony-stimulating factor and interleukin-6 by a human lung cancer cell line, KSNY: gene amplification and increased mRNA stability Eur J Haematol 47 1991 128 133
9. E.B. Haura, S. Livingston, and D. Coppola Autocrine interleukin-6/ interleukin-6 receptor stimulation in non-small-cell lung cancer Clin Lung Cancer 7 2006 273 275 (Pubitemid 43280031)
10. M. Niiya, K. Niiya, T. Kiguchi, M. Shibakura, N. Asaumi, and K. Shinagawa Induction of TNF-alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells Cancer Chemother Pharmacol 52 2003 391 398 (Pubitemid 37363612)
11. D.C. McMillan, M.M. Elahi, N. Sattar, W.J. Angerson, J. Johnstone, and C.S. McArdle Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer Nutr Cancer 41 2001 64 69 (Pubitemid 34666222)
12. M.M. Elahi, D.C. McMillan, C.S. McArdle, W.J. Angerson, and N. Sattar Score based on hypoalbuminemia and elevated C-reactive protein predicts survival in patients with advanced gastrointestinal cancer Nutr Cancer 48 2004 171 173 (Pubitemid 39045778)
13. S. Wilop, M. Crysandt, M. Bendel, A.H. Mahnken, R. Osieka, and E. Jost Correlation of C-reactive protein with survival and radiographic response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer Onkologie 31 2008 665 670
14. A. Koch, H. Fohlin, and S. Sörenson Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy J Thorac Oncol 4 2009 326 332
15. M. Hara, Y. Matsuzaki, T. Shimuzu, M. Tomita, T. Ayabe, and Y. Enomoto Preoperative serum C-reactive protein level in non-small cell lung cancer Anticancer Res 27 2007 3001 3004 (Pubitemid 47228036)
16. C. O'Dowd, L.A. McRae, D.C. McMillan, A. Kirk, and R. Milroy Elevated preoperative C-reactive protein predicts poor cancer specific survival in patients undergoing resection for non-small cell lung cancer J Thorac Oncol 5 2010 988 992
17. O. Schussler, M. Alifano, H. Dermine, S. Strano, A. Casetta, and S. Sepulveda Postoperative pneumonia after major lung resection Am J Respir Crit Care Med 173 2006 1161 1169 (Pubitemid 43726898)
18. O. Schussler, H. Dermine, M. Alifano, A. Casetta, S. Coignard, and N. Roche Should we change antibiotic prophylaxis for lung surgery? Postoperative pneumonia is the critical issue Ann Thorac Surg 86 2008 1727 1733
19. J.G. Lee, B.C. Cho, M.K. Bae, C.Y. Lee, I.K. Park, and D.J. Kim Preoperative C-reactive protein levels are associated with tumor size and lymphovascular invasion in resected non-small cell lung cancer Lung Cancer 63 2009 106 110
20. K.H. Allin, B.G. Nordestgaard, J. Zacho, A. Tybjaerg-Hansen, and S.E. Bojesen C-reactive protein and the risk of cancer: a mendelian randomization study J Natl Cancer Inst 102 2010 202 206
21. H.A. Wakelee, J.H. Schiller, and D.R. Gandara Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the New Intergroup Trial Clin Lung Cancer 8 2006 18 21 (Pubitemid 44336239)